|
Name |
Isoleucyl-Proline
|
Molecular Formula | C11H20N2O3 | |
IUPAC Name* |
(2S)-1-[(2S,3S)-2-amino-3-methylpentanoyl]pyrrolidine-2-carboxylic acid
|
|
SMILES |
CC[C@H](C)[C@@H](C(=O)N1CCC[C@H]1C(=O)O)N
|
|
InChI |
InChI=1S/C11H20N2O3/c1-3-7(2)9(12)10(14)13-6-4-5-8(13)11(15)16/h7-9H,3-6,12H2,1-2H3,(H,15,16)/t7-,8-,9-/m0/s1
|
|
InChIKey |
BBIXOODYWPFNDT-CIUDSAMLSA-N
|
|
Synonyms |
Isoleucyl-Proline; 37462-92-3; H-Ile-Pro-OH; ile-pro; L-isoleucyl-L-proline; Isoleucylproline; L-Proline, L-isoleucyl-; (2S)-1-[(2S,3S)-2-amino-3-methylpentanoyl]pyrrolidine-2-carboxylic acid; CHEMBL1807684; CHEBI:74076; L-Ile-L-Pro; SCHEMBL231857; DTXSID70332168; ZINC1591038; BDBM50348850; MFCD02259535; AKOS010419475; Q27144389
|
|
CAS | 37462-92-3 | |
PubChem CID | 444876 | |
ChEMBL ID | CHEMBL1807684 |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 228.29 | ALogp: | -1.8 |
HBD: | 2 | HBA: | 4 |
Rotatable Bonds: | 4 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 83.6 | Aromatic Rings: | 1 |
Heavy Atoms: | 16 | QED Weighted: | 0.746 |
Caco-2 Permeability: | -5.889 | MDCK Permeability: | 0.00140286 |
Pgp-inhibitor: | 0.01 | Pgp-substrate: | 0.007 |
Human Intestinal Absorption (HIA): | 0.3 | 20% Bioavailability (F20%): | 0.004 |
30% Bioavailability (F30%): | 0.004 |
Blood-Brain-Barrier Penetration (BBB): | 0.949 | Plasma Protein Binding (PPB): | 10.70% |
Volume Distribution (VD): | 0.373 | Fu: | 80.98% |
CYP1A2-inhibitor: | 0.011 | CYP1A2-substrate: | 0.067 |
CYP2C19-inhibitor: | 0.056 | CYP2C19-substrate: | 0.185 |
CYP2C9-inhibitor: | 0.016 | CYP2C9-substrate: | 0.308 |
CYP2D6-inhibitor: | 0.058 | CYP2D6-substrate: | 0.191 |
CYP3A4-inhibitor: | 0.013 | CYP3A4-substrate: | 0.067 |
Clearance (CL): | 8.273 | Half-life (T1/2): | 0.778 |
hERG Blockers: | 0.015 | Human Hepatotoxicity (H-HT): | 0.596 |
Drug-inuced Liver Injury (DILI): | 0.241 | AMES Toxicity: | 0.003 |
Rat Oral Acute Toxicity: | 0.034 | Maximum Recommended Daily Dose: | 0.03 |
Skin Sensitization: | 0.124 | Carcinogencity: | 0.02 |
Eye Corrosion: | 0.004 | Eye Irritation: | 0.032 |
Respiratory Toxicity: | 0.201 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC000749 | 0.680 | D0I0EG | 0.612 | ||||
ENC000810 | 0.591 | D00SEB | 0.393 | ||||
ENC000918 | 0.484 | D0N5HJ | 0.388 | ||||
ENC001906 | 0.462 | D07HGR | 0.323 | ||||
ENC000141 | 0.422 | D0X5SJ | 0.322 | ||||
ENC000001 | 0.306 | D03KYG | 0.299 | ||||
ENC002115 | 0.304 | D0E1XL | 0.276 | ||||
ENC001303 | 0.281 | D08BTB | 0.264 | ||||
ENC004972 | 0.277 | D01STB | 0.260 | ||||
ENC005975 | 0.277 | D0N4EC | 0.258 |